HIV-1 Trans-activator of transcription (Tat) protein (HIV-1 Tat)

HIV-1 Trans-activator of transcription (Tat) is a small regulatory protein (approximately 86-101 amino acids) essential for the efficient transcription of the HIV-1 genome (UniProt P04608). It functions by binding to the trans-activation response (TAR) RNA element at the 5' end of nascent viral transcripts, recruiting the positive transcription elongation factor b (P-TEFb) complex to the viral promoter to stimulate transcriptional elongation (PubMed: 23233516). Beyond its intracellular role, Tat is actively secreted by infected cells and exerts 'bystander' effects on uninfected cells, contributing to chronic inflammation, immune dysfunction, and HIV-associated neurocognitive disorders (HAND) (PubMed: 25101810). As a therapeutic target, Tat is critical because it is expressed early in the viral life cycle and is necessary for the transition from latency to active replication. Antigenic epitopes of Tat, particularly in the N-terminal and basic domains, are the focus of therapeutic vaccine development (e.g., Tat Oyi) aimed at inducing neutralizing antibodies to control viral load and prevent disease progression (PubMed: 25585877). Experimental small-molecule inhibitors, such as didehydro-cortistatin A (dCA), also target the Tat-TAR interaction to enforce a 'block and lock' state of viral latency (PubMed: 28754707).

Other names

Tat proteinTrans-activator of transcriptionp14HIV-1 TatTat antigenic epitopes

Therapeutic vaccines target specific antigenic epitopes to induce neutralizing antibodies that sequester extracellular Tat, preventing its uptake by bystander cells and inhibiting its role in viral trans-activation (PubMed: 25585877). Small molecule inhibitors target the Tat-TAR interaction or the recruitment of P-TEFb to suppress viral transcription from the LTR promoter, potentially enforcing a state of permanent viral latency (PubMed: 28754707).